Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 2/2014

01-02-2014

Thrombosis on a mechanical mitral valve anticoagulated with dabigatran

Authors: Stephanie Coulter, Karla Campos

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2014

Login to get access

Excerpt

Thrombosis of a mechanical heart valve is life-threatening. The overall risk of valve thrombosis is low, with an annual risk of 0.2–0.4 % [1]. Mechanical valves in the mitral position are at a greater risk of thrombosis (1.0–3.8 %) than those placed in the aortic position (0.1–0.6 %) [2, 3]. Lifelong oral anticoagulation therapy is essential for preventing thromboembolic events after implantation of a mechanical heart valve. …
Appendix
Available only for authorised users
Literature
1.
Roudaut R, Serri K, Lafitte S (2009) Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart 93:137–142CrossRef
2.
Foley PW, Sharma R, Kalra PR (2007) Beware of prosthetic valve thrombosis despite therapeutic anticoagulation. Emerg Med J 24:e18PubMedCrossRef
3.
Lengyel M (2008) Diagnosis and treatment of left-sided prosthetic valve thrombosis. Expert Rev Cardiovasc Ther 6:85–93PubMedCrossRef
4.
Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956PubMedCrossRef
5.
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 364:2342–2352CrossRef
6.
Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRef
7.
Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992PubMedCrossRef
8.
Redondo S, Martinez MP, Ramajo M, Navarro-Dorado J, Barez A, Tejerina T (2011) Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol 4:53PubMedCentralPubMedCrossRef
9.
Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB et al (2012) A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 163:931–937PubMedCrossRef
10.
US Food and Drug Administration (2012) FDA drug safety communication: Pradaxa (dabigatran etexiliate mesylate) should not be used in patients with mechanical prosthetic heart valves. US Department of Health and Human Services. www.​fda.​gov/​Drugs/​DrugSafety/​ucm332912.​htm. Accessed 10 April 2013
11.
Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, EM PL, Warfarin Reversal Consensus Group (2004) Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 181:492–497PubMed
12.
13.
Vahanian A, Baumgartner H, Bax J et al (2007) Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European society of cardiology. Eur Heart J 28:230–268PubMed
14.
Salem DN, O’Gara PT, Madias C, Pauker SG, American College of Chest Physicians (2008) Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl):593S–629SPubMedCrossRef
15.
Bonow RO, Carabello BA, Chatterjee K et al (2008) 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol 52:e1–e142PubMedCrossRef
16.
Prince J, Hynes M, Labinaz M, Ruel M, Boodhwani M (2012) Mechanical valve thrombosis with dabigatran. J Am Coll Cardiol 60:1710–1711CrossRef
17.
Stewart RA, Astell H, Young L, White HD (2012) Thrombosis on a mechanical aortic valve whilst anticoagulated with dabigatran. Heart Lung Circ 21:53–55PubMedCrossRef
Metadata
Title
Thrombosis on a mechanical mitral valve anticoagulated with dabigatran
Authors
Stephanie Coulter
Karla Campos
Publication date
01-02-2014
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2014
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-0935-7

Other articles of this Issue 2/2014

Journal of Thrombosis and Thrombolysis 2/2014 Go to the issue

OriginalPaper

D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy

OriginalPaper

Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2)

OriginalPaper

Retinal artery occlusions in children

OriginalPaper

Short-term central venous catheter complications in patients with sickle cell disease who undergo apheresis

Report

Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG®) to guide decision-making

OriginalPaper

The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits